-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Can We Use Epigenetics to Prime Chemoresistant Lymphomas?

Program: Education Program
Session: Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
Hematology Disease Topics & Pathways:
Biological, antibodies, therapy sequence, Diseases, Lymphoma (any), Non-Biological, Therapies, Combinations, checkpoint inhibitors, chemotherapy, enzyme inhibitors, Biological Processes, immunotherapy, epigenetics, Lymphoid Malignancies, Clinically relevant, immune mechanism
Monday, December 7, 2020, 11:25 AM-11:30 AM

Jennifer E. Amengual, MD

Columbia University, New York, NY

Disclosures: Amengual: Karyopharm: Consultancy; Appia Pharmaceuticals: Research Funding.

OffLabel Disclosure: